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Abstract 
Several epidemiological, pre-clinical and clinical studies support Vitamin D as a preventive and therapeutic cancer agent. 
Background 
Vitamin D and cancer: calcitriol, the biologically active form of vitamin D (1,25(OH)D), exerts its effects mainly through binding to 
nuclear vitamin D receptor (VDR). Calcitriol has been shown to be an anti-proliferative, pro-differentiation, pro-apoptotic agent and an 
inhibitor of cell migration. Animal and human in vitro studies strongly indicate that vitamin D may have benefits for many forms of cancer. 
Inadequate levels of circulating 25-hydroxy-vitamin D (25(OH)D) are associated with an increased risk and poor prognosis of several 
types of cancer. 
Vitamin D and melanoma: cutaneous malignant melanoma (CMM) represents a major public health issue: rates in Italy have almost 
doubled in the last decade and CMM is frequent among young adults. For resected stage II melanoma no standard adjuvant treatment 
exists and five-year overall survival is about 70%. 
Cultured melanoma cells can synthesize calcitriol from 25(OH)D and express the VDR. Moreover, 1,25(OH)D has anti-proliferative and 
pro-differentiation effects in human melanoma cells. 1,25(OH)D has been shown to induce apoptosis in human melanoma cell lines and 
has an inhibitory effect on the spreading of melanoma cells in vitro. 
Preliminary results on vitamin D: epidemiological data indicate that vitamin D deficiency is relatively common in Europe. In an Italian 
study, we found that 85% of the participants had insufficient levels of 25(OH)D. We have shown through a meta-analysis of randomized 
trials that vitamin D supplementation is associated with a significant reduction (7%) in total mortality in healthy subjects and an 
association between VDR and 25(OH)D and CMM progression has also been demonstrated. We have also reported significant 
associations between VDR polymorphisms and incidence of skin cancer. In early supplementation trials, the lack of effect on cancer 
incidence has been attributed to insufficient vitamin D supplementation, stressing the need to better study vitamin D bioavailability. 
In fact, a recent IARC report highlighted the need for new randomized trials, based on results from our meta-analyses on 25(OH)D serum 
levels and cancer risk. 
Clinical trial and biomarkers studies: in order to assess whether vitamin D supplementation could improve prognosis of CMM, an 
Italian multi-centre trial in stage II resected melanoma patients was planned to monitor changes in 25(OH)D. The study will address two 
important questions regarding the relationship between the biology of VDR and (1) vitamin D metabolism, and (2) CMM prognosis. This 
will involve investigating the association between VDR polymorphisms and Breslow thickness, the most important prognostic factor of 
CMM, and between 25(OH)D serum level, vitamin D supplementation and VDR. 
We will also evaluate at baseline whether VDR polymorphisms are associated with Breslow thickness and whether we obtain significant 
increase in 25(OH)D serum levels during the first year of supplementation. We will quantify the percentages of patients who have 
desirable levels of 25(OH)D and, if they don’t, the mean time to reach that level. The findings from this study will be of great interest 
because vitamin D could have anti-cancer benefits for a wide spectrum of cancers. 
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Background and rationale 
Biological background 
Cancer chemoprevention uses natural, synthetic or biologic 
agents to reverse, suppress or prevent carcinogenic 
progression. Genetic changes exist throughout the process and 
increase the likelihood that one or more pre-malignant and 
malignant lesions may develop within that process. Multi-step 
carcinogenesis describes a stepwise accumulation of 
alterations, both genotypic and phenotypic. Arresting one or 
several of the steps may impede or at least delay the 
development of cancer. 
Several epidemiological, pre-clinical and clinical studies support 
vitamin D as a preventive and therapeutic cancer agent, for a 
wide spectrum of cancers. 
Calcitriol (1,25-dihydroxyvitamin D [1,25(OH) D]), the hormonal 
derivative of vitamin D, has been established since the 1980s 
as an anti-proliferative and pro-differentiation agent and as a 
pro-apoptotic agent and an inhibitor of cell migration, which may 
imply an inhibitory effect on cancer [1]. 
Vitamin D is indeed more like a hormone and not strictly a 
vitamin according to the classical criteria that an essential 
nutrient is a substance the body cannot synthesize in sufficient 
quantities itself. Also, vitamins are usually involved in 
biochemical reactions, while 1α,25-dihydroxyvitamin D exerts its 
action via VDR. 
Vitamin D represents a group of fat-soluble pro-hormones, the 
two major forms of which are vitamin D2 (or ergocalciferol) and 
vitamin D3 (or cholecalciferol). Endogenous synthesis of vitamin 
D3 takes place in the skin under the influence of ultra-violet B 
(UVB) radiation. Exogenous vitamin D2 or D3 comes from 
dietary intake. The overall vitamin D intake is the sum of 
cutaneous vitamin D and nutritional vitamin D. 
Vitamin D on its own has no physiological action. To be 
physiologically active, vitamin D must first be hydroxylated in 
the liver by the enzyme 25-hydroxylase, encoded by CYP27A1 
(also called the 25-hydroxylase or 25(OH)D), into 25-
hydroxyvitamin D. The 25-hydroxyvitamin D is inactive, and an 
additional hydroxylation in the kidney by the enzyme 1α-
hydroxylase, encoded by CYP27B1 (also called 41α-
hydroxylase), is necessary to produce the physiologically active 
vitamin D metabolite, calcitriol or 1,25(OH)D. When 1,25(OH)D 
is sufficiently available, the enzyme mitochondrial protein
  encoded by CYP24A1 metabolises the 1,25(OH)D into 
1α,24,25-dihydroxyvitamin D, which is further catabolised to 
calcitroic acid. 25(OH)D and 1,25(OH)D are transported in 
serum by the vitamin D-binding protein (GC). Ahn et al 
systematically investigated the association of 48 SNPS in four 
vitamin D metabolising genes (CYP27A1, GC, CYP27B1 and 
CYP24A1) with serum 25(OH)D levels. Four tagSNPS in GC, 
the major serum 25(OH)D carrier, were associated with 
25(OH)D levels [2].  
VDR and cancer risk 
The vitamin D receptor (VDR) gene is involved in multiple 
pathways that may be important in the aetiology of cancer. The 
importance of dietary calcium, vitamin D, energy and fat in 
modifying the association between VDR genotype and cancer 
risk has been shown repeatedly. In addition to these dietary 
factors that modify cancer risk, BMI and age also appear to be 
'effect modifiers' of the association between VDR and cancer. 
We performed a meta-analysis on the association between the 
two most studied VDR polymorphisms (FokI and BsmI) and 
cancer at any site. When comparing FokI ff with FF carriers, we 
found a significant increase in skin cancer (SOR; 95% 
confidence intervals (CI): 1.30; 1.04-1.61) and breast cancer 
(SOR; 95%CI: 1.14; 1.03-1.27) risk. For the same genotype 
comparison, we found a significantly higher risk of cancer when 
we pooled estimates from cancer sites possibly associated with 
vitamin D levels (prostate, breast, skin, ovary, non-Hodgkin 
lymphoma). A significant reduction in prostate cancer risk was 
observed for carriers of BsmI Bb compared with bb genotype 
(SOR; 95%CI: 0.83; 0.69-0.99). In Caucasian populations, both 
Bb and BB carriers had a significant reduced risk of cancer at 
any site. In conclusion, this meta-analysis showed that VDR 
FokI and BsmI polymorphisms may modulate the risk of cancer 
of the breast, skin and prostate and possibly affect cancer risk 
at any site in Caucasians [3].  
Sources of vitamin D 
There is good evidence from randomized trials that a dietary 
intake of vitamin D increases serum levels of 25-hydroxyvitamin 
D [4]. However, only a few foods naturally contain appreciable 
enough amounts of vitamin D to have an impact either through 
the form of cholecalciferol (vitamin D3) derived from animal 
sources, or ergocalciferol (vitamin D2), from plant food. It has 
been verified that fatty fish such as salmon, mackerel and 
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bluefish, cod-liver oil, egg yolks, sun-dried mushrooms and 
yeasts are excellent sources of vitamin D3. 
Most of an individuals vitamin D supply is provided through 
endogenous synthesis of vitamin D3 upon sunshine exposure 
and will depend on amounts of UVB reaching earth surface, on 
skin surface exposed to UVB and on skin pigmentation. Many 
factors influence the amount of UVB radiation reaching the 
Earth’s surface. 
In summary, these factors include: 
•  UVB is mainly present in sunlight between 10 am and 3 pm 
solar hours. 
•  The season: UVB is more abundant during the summer or 
the hot season. 
•  Place of residence. 
•  Meteorology: clouds may filter out much of the UVB, even 
at the equator. 
•  The UVB-induced synthesis of vitamin D3 in human skin is 
additionally dependent on several factors, including: 
time spent out-of-doors (evaluation of continuous 
pattern versus intermittent pattern of sun exposure); 
skin type, pigmentation; 
age of subjects, as endogenous skin synthesis 
capacity decreases with age; 
•  Sun protection habits, mainly in populations where clothing 
(garments and veils) covers most of the skin surface.  
•  Results from a study by Adams et al [61] also show that the 
serum level of 25(OH)D is more stable than vitamin D. 
Because of its relatively long half-life (τ1/2 = 12.9 (SD: 3.6 
d)) [5], the serum 25(OH)D level is considered as the best 
gauge of individual vitamin D status. 
Vitamin D and mortality from all causes 
We published a meta-analysis of published randomized trials, 
which showed a significant reduction of 7% in total mortality (RR 
0.93, p<0.05) in subjects taking vitamin D. Eighty-two percent of 
patients received vitamin D3 (cholecalciferol), the remaining 
vitamin D2 (ergocalciferol), either orally or by injection. Average 
daily doses ranged from 300 to 2000 IU. Treatment ranged from 
daily to four-monthly, and follow-up ranged from six months to 
seven years. Our main recommendation in light of the results 
from this study was the conduction of large population-based 
randomized trials of prolonged vitamin D3 treatment [6]. The
 Netherlands Longitudinal Aging Study examined, during a six-
year follow-up, the risk of death of 1260 community dwelling 
people 65 years old or more according to serum 25(OH)D levels 
measured at baseline [7]. The results indicated that subjects 
with serum 25(OH)D levels lower than 20 ng/ml had a mortality 
risk associated with steadily lower levels (log-rank test: 
p<0.0001). 
In the Third National Health and Nutrition Examination Survey 
(NHANES III, USA) 13,331 adults, 20 years or older, were 
followed for a median of 8.7 years [8]. There were 1806 deaths, 
777 from cardiovascular disease (CVD) and 424 from cancer. 
Serum 25(OH)D levels below 17.8 ng/ml were associated with a 
26% increased rate of all-cause mortality [mortality rate ratio 
(95% CI: +8%; +46%)].  
Epidemiological evidence and optimal serum levels 
of 25(OH)D 
So far epidemiological data for cancer prognosis argue for an 
overall positive role of sun-induced vitamin D. The ratios of 
death rates to incidence rates suggest that cancer prognosis 
improves with decreasing latitude. UV exposure is a realistic 
explanation since it is unlikely that cancer treatment is better in 
Australia than in the United Kingdom [9]. 
Genetic variations would be phenotypically apparent as inter-
individual variations in limiting rates of vitamin D synthesis in the 
skin, hydroxylation in the liver and in the kidney, transport, 
metabolism, degradation would ultimately influence individual 
vitamin D status. These genetic differences would also be 
reflected in the numerous variants of the VDR, some of which 
have different affinity for 1,25(OH)D. 
In general modern society is vitamin D deprived compared with 
prehistoric humans. The concentrations of 25(OH)D observed 
today are based on contemporary cultural norms (clothing, sun 
avoidance, food choices and legislation).  
Inadequate levels of circulating 25(OH)D are associated with an 
increased risk and poor prognosis of several types of cancer 
[10–12].  
Giovannucci estimated the relationship between plasma 
25(OH)D and several risk factors (skin colour, obesity, latitude 
and physical activity) for cancer. The associations between 
these factors and total cancer incidence and mortality in their 
large cohort (~50,000 subjects) could be accounted for an by an 
increment of 25 nmol/l in 25(OH)D, which reduces mortality by 
29% for all cancers and 45% for digestive cancers [10]. These 
results are consistent with a marked direct effect of vitamin D on 
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cancer incidence and mortality, but they could be at least partly 
due to confounding factors. This can be resolved only by a 
randomized trial. 
A prospective study examined the association between pre-
diagnostic 25(OH)D levels and mortality in patients diagnosed 
with colorectal cancer within the Nurses' Health Study (NHS) 
and the Health Professionals Follow-Up Study (HPFS). This 
study showed that higher pre-diagnostic plasma 25(OH)D levels 
were associated with a significant improvement in overall 
survival [13]: individuals with vitamin D levels in the highest 
quartile were 48% less likely to die (from any cause) than those 
with the lowest vitamin D levels (adjusted HR of 0.52: 95% CI, 
0.29 to 0.94), with a linear and statistically significant trend. The 
odds of dying from colon cancer specifically were 39% lower 
(HR of 0.61; 95% CI, 0.31 to 1.19). The authors highlight the 
need for well-designed prognostic studies among cohorts of 
cancer patients, in which exposure assessments are uniformly 
obtained after diagnosis and information on prognostic tumour 
characteristics is also available. Several studies show promising 
results, but a randomized trial among cancer patients would be 
essential to obtain an unequivocal answer on whether cancer 
patients should be advised to take vitamin D supplements [14]. 
A German cohort study of 3299 patients referred for coronary 
angiography recorded, during a median 7.8 years of follow-up, 
736 deaths, among which 95 were attributed to a cancer [15]. 
After adjusting for common confounders (e.g. sex, age, obesity, 
smoking status, physical exercise) the study found a twofold 
increased risk (95% CI: 1.01-3.8) for a cancer-related death in 
patients with serum 25(OH)D levels below 15 ng/ml, as 
compared to patients with higher serum concentrations. This 
risk did not vary in patients with serum levels higher than 15 
ng/ml. 
A working group of experts, organized by the International 
Agency for Cancer Research, carried out meta-analyses on 
25(OH)D serum levels and colorectal cancer incidence. We 
observed a significant reduction in risk comparing the highest 
levels versus the lowest level of 25(OH)D; pooled RR: 0.6 
(95%CI: 0.4, 0.7), with a significant dose-response effect. 
Among the studies included, the lowest values of 25(OH)D for 
the upper categories in average were 34 mg/ml and the upper 
levels of the lowest category was 18 mg/ml [59]. 
Vitamin D deficiency is defined by most experts as a 25(OH)D 
level of less than 20 ng/ml (50 nmol/l) [16,17]. By these 
standards both the European and US populations are vitamin D 
insufficient or deficient. The total 25(OH)D, that is 25(OH)D2 
plus 25(OH)D3, is what physicians need to be aware of in their 
patients. 
The estimated optimal serum 25(OH)D level for prevention of 
colorectal carcinoma and adenoma is 90 nmol/l or higher, a 
conclusion supported by the NIH-sponsored symposium on 
vitamin D and cancer [18,19]. 
In a trial (IEO 007) carried out by our Cancer Prevention and 
Genetics Division in pre-menopausal Italian women at high risk 
of breast cancer, we found that 85% had at insufficient level of 
25(OH)D, considering as cut-off point 75nmol/l. The results 
were presented at the AACR (2008). 
Current efforts to assess optimal serum concentrations of 
25(OH)D generally focus on bone health in older white persons, 
and the common definition of the optimal level has been the 
concentration that maximally suppresses serum parathyroid 
hormone (PTH). In most persons, the optimal level cannot be 
reached with the currently recommended intake of 200 and 600 
IU/d for younger and older adults, respectively. 
The Women’s Health Initiative (WHI) in the USA [20], a 
randomized trial evaluating the influence of 400 IU of vitamin D 
supplementation per day, plus calcium, showed negative results 
on all cancer risk. However, findings from the nested case-
control study demonstrated a significant inverse trend with lower 
baseline levels of serum 25(OH)D associated with an increased 
risk of colorectal cancer (p for trend = 0.02). Commentaries on 
the negative findings of the WHI trial suggest that too-low 
vitamin D doses, too-short trial duration, addition of calcium and 
low compliance to supplementation may be an explanation 
[21,22]. 
The results of the nested case-control study organised within 
the WHI trial including colorectal cancer cases and 317 
matched controls, showed that the risk of colorectal cancer 
increased with decreasing serum 25-hydroxyvitamin D levels in 
subjects with low-vitamin D status at baseline, before use of 
supplements or placebo. Results from these trials stress the 
need to better study vitamin D bio-availability. 
A recent study on prognostic effects of circulating 25(OH)D in a 
cohort of patients with early breast cancer found that deficient 
levels of vitamin D were associated with higher grade tumours, 
suggesting that the prognostic effect of vitamin D may be due, 
in part, to the development of higher grade tumours in vitamin 
D-deficient women, consistent with a potential role of vitamin D 
in breast carcinogenesis [23]. 
Safety and toxicity of vitamin D 
Cholecalciferol accumulates in adipose and muscular tissue to 
be available when the body needs it. 
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A daily treatment of 2000 IU of Vitamin D3, the safe upper-intake 
limit as defined by the National Academy of Sciences, should 
increase circulating 25(OH)D to the desired level. 
Thus 2000 IU is the safe recommended daily allowance even at 
the higher end of the normal 25(OH)D serum concentration 
level [24–29]. 
All the published reports of Vitamin D toxicity with convincing 
evidence of hypercalcemia involve serum 25(OH)D 
concentrations well above 200 nmol/l, which requires a daily 
intake of more than 40, 000IU, and which could be 
conservatively considered the lowest observed adverse effect 
level (LOAL). 
Vitamin D intoxication is observed when serum levels of 25-
hydroxyvitamin D are greater than 150 ng/ml (374 nmol/l). 
Vitamin D intoxication is extremely rare but can be caused by 
inadvertent or intentional ingestion of excessively high doses. 
Doses of more than 50,000 IU/d raise levels of 25(OH)D to 
more than 150 ng/ml (374 nmol/l) and are associated with 
hypercalcemia and hyperphosphatemia [30,31,32]. 
Trivedi et al in their trial on fractures and mortality reported no 
side effects in over 2000 subjects aged 65 or over receiving 2.5 
mg po four-monthly or placebo for five years [33]. The Women’s 
Health Initiative trial reported a 17% increase in the risk of 
kidney stones among post-menopausal women receiving 10 μg 
of vitamin and 1000 mg of elemental calcium per day [34], but 
this was probably due to the calcium supplements, and not the 
vitamin D supplement. Other randomized trials testing vitamin D 
supplementation did not report higher incidence of kidney 
stones [4]. 
Compliance 
In the study by Trivedi et al a compliance of at least 80% (≥ 12 
of 15 tablets posted four-monthly over five years) was achieved 
in 76% of randomized subjects. In this study, subjects received 
tablets four-monthly, with a freepost reply to report whether the 
tablet was taken and reasons for not taking it [33]. However, in 
the WHI study compliance to supplementation was low. 
Throughout the entire trial duration, only 50–60% of women 
took 80% of the scheduled supplementation regimen [20]. 
In our meta-analysis of 18 randomized trials on intakes of 
vitamin D and overall mortality, eight of these trials reported 
increases in serum 25-hydroxyvitamin D level in the intervention 
group, but variations ranged from a factor 1.4-5.2 mainly 
because of compliance issues [6]. 
Vitamin D and melanoma, epidemiological evidence 
Relatively few epidemiologic studies have directly addressed 
the relationship between vitamin D and the incidence or 
prognosis of cutaneous malignant melanoma (CMM). 
Increasing incidence of skin cancer starting around the 1950s 
has been described in all light-skinned populations. These 
increases concerned all types of skin cancer. The most recent 
cancer registry data show that skin cancer incidence is still 
rising in nearly all light-skinned populations. Cutaneous 
malignant melanoma represents a major public health problem 
in many countries throughout the world. Over the past several 
decades, its incidence has increased more rapidly than that of 
any other cancer, although fortunately this increase has not 
been accompanied by a similar rise in mortality rates, possibly 
reflecting beneficial effects of awareness and prevention 
programmes. In Italy, the age-adjusted incidence is 4.6 per 
100,000 person per year in males and 5.5 in females, with 
higher mortality rates being documented in Northern rather than 
in Southern Italy [35-37]. In Italy, the incidence of CMM has 
increased: rates have almost doubled in the last ten years. 
CMM is a disease of young subjects (>50% of all cases are 
diagnosed below the age of 60 years), and for Stage II 
melanoma no treatment can be offered to the patients after 
surgery. 
The CMM fatality over five years was observed to be 40–60% 
less in people with a history of high sun exposure independently 
of body site, thickness, mitotic rate and early detection 
behaviour. The study by Berwick et al involved mostly patients 
with early stage melanoma, and it is plausible that the known 
anti-proliferative and anti-angiogenic properties of vitamin D 
may be inversely associated with melanoma progression. 
However, it should be noted that solar elastosis and other sun 
exposure markers in the study reflected pre-diagnostic 
exposures to sunlight [38]. Sunburn and intermittent sun 
exposure are well-known risk factors for CMM; however, 
continuous pattern of sun exposure seems to be inversely 
associated to melanoma [39,40]. Thus, it is not clear whether 
the results of Berwick et al reflect benefits related to continued 
sunlight exposure and an association with vitamin D intake, or a 
different pathogenesis in melanomas that arise in persons at 
risk to develop actinic skin damage. 
Exposure to UVB increases endogenous vitamin D synthesis 
and risk of skin cancer. However, skin synthesis of vitamin D is 
self-limited and in light-skinned people fades away after 5–10 
minutes. Longer durations of sun exposure will not further 
increase vitamin D, but will increase skin cancer risk.
 5  www.ecancermedicalscience.com 
R
e
v
i
e
w
s
 ecancer 2009, 3:160 
 
Furthermore, within an IARC working group, we showed that 
exposure to artificial UV light from sun beds increases the risk 
of melanoma and SCC, especially when the first exposure takes 
place before 35 years of age [41]. 
The incidence of melanoma of the skin on intermittently 
exposed sites is reduced among outdoor workers compared 
with indoor workers [42]. This pattern of incidence among 
workers has usually been attributed to the fact that a more 
continuous pattern of sun exposure may reduce the incidence of 
sunburns, a known melanoma risk factor. However, an 
alternative hypothesis is that outdoor workers are less likely to 
be deficient in vitamin D because of their more regular exposure 
to sunlight. 
Seasonal variation in serum 25(OH)D levels is well known [43], 
and the winter level of serum 25(OH)D is considered the best 
indicator of an individual’s real vitamin D status. 
Boniol  et al showed significant variations in incidence and 
fatality of melanoma with relation to season of diagnosis. There 
was also a 16% (95% CI: −6%;  −28%) decrease in the 
multivariate adjusted fatality rate between winter and summer 
after adjustment for Breslow thickness, suggesting other factors 
apart from earlier diagnosis influence survival, for instance a 
late promotional effect of greater exposure to UV in the summer 
[44]. An Italian study found significantly increased survival in 
melanoma patients who had intermittent sun exposure before 
diagnosis [45]. 
A study population of 212 patients with histologically proven 
cutaneous melanomas showed that progression of malignant 
melanoma was associated with statistically significantly reduced 
25(OH)D serum levels [46]. 
Vitamin D and melanoma, biological evidence 
Cultured melanoma cells can synthesize 1,25(OH)2D3 from 
25(OH)D3, express the VDR and proliferate more slowly in 
response to 1,25(OH)2D3 [47–49]. Moreover, 1,25(OH)2D3 has 
been shown to suppress the growth of human malignant 
melanoma (MM)-derived xenografts (expressing the VDR) in 
immunosuppressed mice, but not in a VDR-negative MM cell 
line. The 1,25(OH)2D3 molecule has been shown to induce 
apoptosis in a human MM cell line in vitro, and an inhibitory 
effect on the spread of MM cells has been demonstrated in vitro 
[50]. 
Upon the activation by 1,25(OH)2D3, the VDR mediates its 
effects by regulating the transcription of other genes. The VDR 
gene is located on chromosome 12q12-q14, and it has at least 
196 single nucleotide polymorphisms, some of which seem to 
influence the activity of 1,25(OH)2D3. Among VDR 
polymorphisms, the most frequently investigated for their 
association with various cancers are FokI (exon 2, rs10735810), 
which results in an altered translation start site and has been 
shown to be functionally relevant [51], and BsmI (intron 8, 
rs1544410), which seems to be associated with different 
diseases, although its function is still under debate [52,53]. 
A meta-analysis on vitamin D receptor 
polymorphisms and skin cancer 
A meta-analysis suggests a possible significant role of VDR 
FokI and BsmI polymorphisms in CMM and non-melanoma skin 
cancer (NMSC): the FokI f allele showed a positive association 
with CMM and NMSC, whereas the BsmI B allele showed a 
significantly negative association with CMM [54]. Further studies 
on the role of VDR polymorphisms in skin cancer development 
could be useful to better understand these associations. 
Serum levels of 25(OH)D, VD R and melanoma 
prognosis 
A cohort study was carried out in Leeds (UK) to test the 
hypothesis that higher vitamin D levels reduce the risk of 
relapse from melanoma. A prospective survival analysis in this 
cohort of 872 patients showed that higher 25-hydroxyvitamin D3 
levels, at diagnosis were associated with lower Breslow 
thickness at diagnosis (p=0.002) and were independently 
protective of relapse and death: the hazard ratio for relapse-free 
survival (RFS) was 0.79 (95% CI, 0.64 to 0.96; p=0.01) for a 20 
nmol/l increase in serum level. There was evidence of 
interaction between the vitamin D receptor (VDR) BsmI 
genotype and serum 25-hydroxyvitamin D3 levels on RFS [55]. 
Two studies evaluating serum levels of 25(OH)D and skin 
cancer risk [46,56] reported lower basal 25(OH)D levels in 
melanoma patients compared to the control group, although this 
difference was statistically not significant. Bishop evaluated the 
risk of relapse for CMM patients taking vitamin D 
supplementation and found a significant reduced risk: 0.54 
(0.32-0.92). The results were presented as an abstract 
publication [56]. Moreover, Nurnberg [46] found that progression 
of malignant melanoma was associated with statistically 
significantly reduced 25(OH)D serum levels. Two other studies 
found an association of VDR polymorphisms with Breslow 
thickness [57,58], suggesting a role for vitamin D in the CMM 
prognosis. 
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Halsall  et al evaluated also a novel adenine-guanine 
substitution -1012 bp relative to the exon 1a transcription start 
site (A-1012G) of the vitamin D receptor. The A allele was over-
represented in CMM patients (p=0.007). The outcome was 
related to the development of metastasis, the Kaplan-Meier 
estimates of the probability of metastasis at five years being: 
GG 0%; AG 9%, CI 4-16%; AA 21%, CI 12-36%; (p=0.008), and 
to thicker Breslow thickness groups (p=0.04). The effect on 
metastasis was independent of tumour thickness and A-1012G 
may have predictive potential, additional to Breslow thickness. 
FokI and TaqI variants were strongly related to the thickest 
Breslow thickness group (p=0.005). There was an interaction 
between the A-1012G and FokI polymorphisms (p=0.025) and 
the FokI variant enhanced the effect of the A allele of the A-
1012G polymorphism on metastasis, the probability of 
metastasis for AAff at a five-year follow-up being 57%, CI 24–
92% [57]. 
The need for a trial on vitamin D supplementation 
Vitamin D is a drug, more precisely, a hormone. The experience 
accumulated in the last 20 years with chemoprevention and 
hormonal substances shows that no compound should be 
recommended for cancer chemoprevention if its efficacy and 
side effects have not been evaluated in large, randomized trials. 
Laboratory data and observational studies should only be 
considered as indicative of potential for chemopreventive use. 
Findings from prospective cohort studies on colorectal cancer 
risk and on mortality constitute pieces of evidence strong 
enough to consider that randomized trials of vitamin D use and 
cancer mortality may not have correctly addressed the question, 
and that new randomized trials should be organized. 
Some groups advocate increasing vitamin D status (e.g. above 
30 ng/ml of serum 25-hydroxyvitamin D) through more exposure 
to ultraviolet radiation or through taking high doses of vitamin D 
supplements (i.e. more than 50 μg/d or more). However, sun 
exposure is also a well-known risk factor for certain cancers 
and, as for any drug, before issuing claims on health benefit and 
promoting recommendations for increasing substantially the 
vitamin D status of millions of individuals, the alleged claims 
must be tested via randomized controlled trials for evaluation of 
efficacy on primary endpoint(s) [59]. 
The issue of the dose 
The estimated optimal serum 25(OH)D for prevention of cancer 
equal to or greater than 30 ng/ml is a conclusion supported by 
the NIH-sponsored symposium on vitamin D and cancer [18,19]. 
Results from the meta-analyses on 25(OH)D serum levels and 
cancer incidence, within the working group of experts, 
organized by the International Agency for Cancer Research, 
showed a significant reduction in risk for colorectal cancer 
comparing the highest levels versus the lowest level of 
25(OH)D, with a significant dose-response effect [59]. Among 
the studies included, the lowest values of 25(OH)D for the upper 
categories on average were about 30 mg/ml and the upper 
levels of the lowest category was 18 mg/ml. 
In a trial (IEO 007) carried out by the Cancer Prevention and 
Genetics Division of the European Institute of Oncology in pre-
menopausal women at high risk of breast cancer, we found that 
85% had insufficient levels of 25(OH)D, considering 30 ng/m as 
cut-off point.  
It has been calculated that 2000 IU/d should shift the NHANES 
III distribution so that only 10–15% of persons had 
concentrations <30 ng/ml, which are observed in healthy 
outdoor workers. 
This dose is not toxic and necessary to achieve the optimal 
level of 25(OH)D. A daily dose of 2000 IU vitamin D3, the safe 
upper intake limit as defined by the National Academy of 
Sciences, should achieve the desired level of circulating 
25(OH)D [17,19,24,26]. 
Cholecalciferol is accumulated in adipose and muscular tissue 
to be available when the body needs it. Vitamin D intoxication is 
extremely rare but can be caused by inadvertent or intentional 
ingestion of excessively high doses. Doses of more than 50,000 
IU/d raise levels of 25-hydroxyvitamin D to more than 150 ng/ml 
(374 nmol/l) and are associated with hypercalcemia and 
hyperphosphatemia [30,31,60]. 
All of the reports of vitamin D toxicity showing the convincing 
evidence of hypercalcemia involve serum 25(OH)D 
concentrations well above 200 nmol/l, which requires a daily 
intake of more than (40,000 IU), and which could be 
conservatively considered the lowest observed adverse effect 
level [28,29]. 
The Women’s Health Initiative trial reported a 17% increase in 
the risk of kidney stones among post-menopausal women 
receiving 10 µg of vitamin and 1000 mg of elemental calcium 
per day 
34, but this increase was probably due to the calcium 
supplements, and not to the vitamin D. In fact other randomized 
trials testing vitamin D supplementation did not report higher 
incidence of kidney stones [4]. 
As a result of these studies, we decided on 100,000 IU every 50 
days, which corresponds to 2000 IU daily, for the following trial 
on melanoma patients. 
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Summary of background and specific aims 
of an Italian multi-centre randomized 
placebo-controlled phase III trial 
Vitamin D and cancer: calcitriol, the biologically active form of 
vitamin D (1,25(OH)D), exerts its effects mainly through binding 
to the nuclear VDR. Calcitriol has been shown to be an anti-
proliferative, pro-differentiation, pro-apoptotic agent and an 
inhibitor of cell migration. Animal and human in vitro studies 
strongly indicate that vitamin D may be beneficial for many 
forms of cancer. Inadequate levels of circulating 25-hydroxy-
vitamin D (25(OH)D) are associated with an increased risk and 
poor prognosis of several types of cancer. 
Vitamin D and melanoma: cutaneous malignant melanoma 
represents a major public health problem—rates in Italy have 
almost doubled in the last decade and CMM is frequent among 
young adults. For resected stage II melanoma no standard 
adjuvant treatment exists and five-year overall survival is about 
70%. 
Cultured melanoma cells can synthesize calcitriol from 25(OH)D 
and express the VDR. Moreover, the anti-proliferative and pro-
differentiation effect of 1,25(OH)D have been found in human 
melanoma cells. 1,25(OH)D has been shown to induce 
apoptosis in human melanoma cell lines and an inhibitory effect 
on the spread of melanoma cells has been demonstrated in 
vitro. 
Preliminary results on vitamin D: Epidemiological data indicate 
that vitamin D deficiency is relatively common in Europe. In an 
Italian study, we found that 85% of the participants had 
insufficient level of 25(OH)D. We show through a meta-analysis 
of randomized trials that vitamin D supplementation was 
associated with a significant reduction of 7% in total mortality in 
healthy subjects. We also reported significant associations 
between VDR polymorphisms and incidence of skin cancer 
while other studies suggest association between VDR and 
25(OH)D and CMM progression. In early supplementation trials, 
the lack of effect on cancer incidence has been attributed to 
insufficient vitamin D supplementation, stressing the need to 
better study vitamin D bioavailability. 
Finally, a recent IARC report highlighted the need for new 
randomized trials, based on results from our meta-analyses on 
25(OH)D serum levels and cancer risk. 
 
Conclusions  
Several epidemiological, pre-clinical and clinical studies support 
vitamin D as a preventive and therapeutic cancer agent, for a
wide spectrum of cancer. The aim of this proposed study is to 
evaluate the effect of vitamin D supplementation on melanoma 
recurrence and mortality.  
 
Overview of study design 
We propose a randomized double-blind placebo-controlled 
clinical trial to evaluate whether vitamin D supplementation and 
changes of serum levels of 25(OH)D are associated with 
melanoma recurrence and mortality. Patients with resected 
stage II melanoma will be recruited in different institutes in Italy. 
Participants will be randomly assigned to one of the arms 
(100,000 IU po every 50 days, an average 2000 IU a day, 
versus placebo), treated for three years and followed for two 
years. 
Recruitment will proceed simultaneously at the different centres 
and will be completed in four years. Complete physical 
examination, measurements of anthropometric and 
epidemiological characteristics, as measure of study 
compliance will be performed at baseline as well as at the 
interim visits, every four months. We will collect blood samples 
to measure vitamin D levels every four months for the first year, 
and annually thereafter. Vitamin D polymorphisms will be 
evaluated at baseline. Efficacy will be determined by assessing 
CMM recurrence as the primary outcome. Three are the 
planned interim analyses. We will also evaluate general and 
CMM specific mortality.  
Compliance will be evaluated by self-reported number of 
ampoules taken, and supported by serum 25(OH)D3 levels. 
The study will be conducted across Italian Institutes sponsored 
by the European Institute of Oncology. The minimum length of 
the follow-up period will be two years, and the end of follow-up 
is determined by recurrence, death or last day of the follow-up.  
 
Aims of the trial 
Primary aim
To assess the effect of Vitamin D3 supplementation (2000 
IU/day) on disease-free survival for stage II CMM patients 
through a randomized, placebo-controlled trial. 
Secondary aims
To evaluate: 
•  whether vitamin D receptors (BsmI,  FokI   and A-1012G 
polymorphisms), gene–gene interactions and serum level 
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of 25(OH)D are associated with melanoma prognosis: we 
will assess the association at baseline between 25(OH)D 
serum levels, vitamin D receptor (VDR) polymorphisms and 
gene–gene interactions with Breslow thickness, the main 
prognostic factors; 
•  whether changes in  25(OH)D are associated with DFS or 
OS; 
•  whether Vitamin D receptors, CYP27A1, CYP24A1 and GC 
(vitamin D binding protein)  genes are associated to serum 
level of 25(OH)D at baseline and with changes in 25(OH)D 
levels; 
•  whether 25(OH)D serum levels of vitamin D are associated 
with BMI, vitamin D food intake and fat intake; 
•  whether vitamin D receptors and 25(OH)D serum levels of 
vitamin D are associated with other prognostic factors such 
as number of mitosis, gender, age, tumour location and 
ulceration; 
•  percentage of patients at 30 mg/ml level of 25(OH)D at one 
year and mean time to reach that level; 
•  change in overall survival (OS) in melanoma patients at 
stage II, taking vitamin D supplementation; 
•  the pattern of response of parathormone (PTH) following 
vitamin D3 supplementation in these patients, and 
association with changes in 25(OH)D; 
•  25(OH)D serum levels and anthropometric measures (such 
as BMI, waist-to-hip ratio, waist-to-stature  ratio), dietary 
intakes (vitamin D, calcium and fat intake), occupation and 
different patterns of sun exposures; 
•  Short and long-term safety and toxicity at 2000 IU/d; 
•  Compliance. 
Finally, we will develop a bio-repository of blood samples, 
collected at several time points. This will create a large 
biological database for future research (e.g. molecular 
characteristics of intervention efficacy, serum, vitamin D serum 
levels). 
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